Rottlaender Andrea, Kuerten Stefanie
Department of Anatomy and Cell Biology, University of Wuerzburg, Wuerzburg 97070, Germany.
Int J Mol Sci. 2015 Jul 1;16(7):14850-65. doi: 10.3390/ijms160714850.
Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS) and characterized by the infiltration of immune cells, demyelination and axonal loss. Loss of axons and nerve fiber pathology are widely accepted as correlates of neurological disability. Hence, it is surprising that the development of neuroprotective therapies has been neglected for a long time. A reason for this could be the diversity of the underlying mechanisms, complex changes in nerve fiber pathology and the absence of biomarkers and tools to quantify neuroregenerative processes. Present therapeutic strategies are aimed at modulating or suppressing the immune response, but do not primarily attenuate axonal pathology. Yet, target-oriented neuroprotective strategies are essential for the treatment of MS, especially as severe damage of nerve fibers mostly occurs in the course of disease progression and cannot be impeded by immune modulatory drugs. This review shall depict the need for neuroprotective strategies and elucidate difficulties and opportunities.
多发性硬化症(MS)是一种中枢神经系统(CNS)的自身免疫性疾病,其特征为免疫细胞浸润、脱髓鞘和轴突损失。轴突丧失和神经纤维病理改变被广泛认为是神经功能障碍的相关因素。因此,长期以来神经保护疗法的发展一直被忽视,这令人惊讶。造成这种情况的一个原因可能是潜在机制的多样性、神经纤维病理的复杂变化以及缺乏生物标志物和量化神经再生过程的工具。目前的治疗策略旨在调节或抑制免疫反应,但并非主要减轻轴突病理改变。然而,靶向性神经保护策略对于MS的治疗至关重要,特别是因为神经纤维的严重损伤大多发生在疾病进展过程中,且无法被免疫调节药物所阻止。本综述将描述神经保护策略的必要性,并阐明困难与机遇。